I think the point she was making is that she would be happy to make a good commercial licensing deal which would include funding the phase 3 trials. But OPT doesn't need to accept disadvantageous terms and she's prepared to raise sufficient funds and go it alone if a reasonable offer isn't received.
Ann: Opthea Completes Successful FDA and EMA Meetings for Phase 3, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.5¢ |
Change
-0.015(2.73%) |
Mkt cap ! $658.6M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 55.0¢ | 53.0¢ | $825.1K | 1.527M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22320 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |